Backers of Jena, Germany-based Inflarx NV have turned their attention to the rest of the pipeline after the stock-jolting news from an independent data monitoring committee (DMC) responsible for the ...

InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to ...

German drug developer InflaRx (Nasdaq: IFRX) saw its US-traded shares plunge 55% to $0.82 in pre-market activity today, as it ...

Treatment of PG is currently limited to immune-suppressing drugs and antibiotics to treat complicating infections, and, in ...

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.

InflaRx (IFRX) stock falls as the company decided to halt studies into its lead asset vilobelimab against pyoderma ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement ...

A Spokane County employee, Ryan Becker, has been facing challenges due to an extremely rare skin condition, but he will keep his job, at least for ...

SPOKANE, Wash. – Ryan Becker, a Spokane resident, is battling an extremely rare skin condition known as pyoderma gangrenosum. After visits to the Mayo Clinic and Johns Hopkins, Becker has been ...

Teresaa was diagnosed with Pyoderma Gangrenosum (PG) in July last year. When medics suggested amputating her right leg, the mum-of-two said she was more than happy to accept because she wanted the ...